Senseonics (NYSE:SENS) announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The FDA issued an alert warning diabetes patients and caregivers about potential issues with smartphone alerts for continuous glucose monitors.

Dr. Medha N. Munshi, geriatrician and founder of Joslin's Geriatric Diabetes Program leads research on improving care for ...

Interview with Dr. Medha Munshi on the Changing Landscape of Diabetes CareMedha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

Devices and Getinge have recently announced their partnership under which they will integrate Getinge’s bioreactors with 908 ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...